Trial Profile
A phase II, multicenter, open-label, randomized-controlled trial evaluating the efficacy and safety of a sequencing schedule of cobimetinib plus vemurafenib followed by immunotherapy with an anti- PD-L1 antibody atezolizumab for the treatment in patients with unresectable or metastatic BRAF V600 mutant melanoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Apr 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Cobimetinib (Primary) ; Vemurafenib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms ImmunoCobiVem
- 24 Apr 2024 This trial has been completed in Germany according to European Clinical Trials Database record.
- 15 Jun 2023 Results (n=135) assessing efficacy of vemurafenib plus cobimetinib to atezolizumab in patients with advanced BRAFV600-positive melanoma published in the European Journal of Cancer
- 07 Jun 2022 Primary endpoint has been met (PFS1: Time to First Documented Disease Progression) , according to Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology